Skip to main content
. 2021 Aug 4;74(9):1572–1578. doi: 10.1093/cid/ciab674

Figure 2.

Figure 2.

Main inverse probability of treatment weighting analysis and subgroup analysis of 90-day recurrent Clostridioides difficile infection. Odds ratio <1 favors bezlotoxumab. Abbreviations: BEZ, bezlotoxumab; CDI, Clostridioides difficile infection; FDX, fidaxomicin; SoC, standard of care; VAN, vancomycin.